Forma Therapeutics Holdings (Forma Therapeutics Holdings) Debt-to-EBITDA : -0.16 (As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Forma Therapeutics Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Forma Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $5.34 Mil. Forma Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $27.21 Mil. Forma Therapeutics Holdings's annualized EBITDA for the quarter that ended in Jun. 2022 was $-209.13 Mil. Forma Therapeutics Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was -0.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Forma Therapeutics Holdings's Debt-to-EBITDA or its related term are showing as below:

FMTX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.19 Med: -0.19 Max: -0.17
Current: -0.17

During the past 4 years, the highest Debt-to-EBITDA Ratio of Forma Therapeutics Holdings was -0.17. The lowest was -0.19. And the median was -0.19.

FMTX's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.37 vs FMTX: -0.17

Forma Therapeutics Holdings Debt-to-EBITDA Historical Data

The historical data trend for Forma Therapeutics Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forma Therapeutics Holdings Debt-to-EBITDA Chart

Forma Therapeutics Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Debt-to-EBITDA

-0.19

Forma Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Debt-to-EBITDA	Get a 7-Day Free Trial										-0.03	-0.18	-0.17	-0.18	-0.16

Competitive Comparison of Forma Therapeutics Holdings's Debt-to-EBITDA

For the Biotechnology subindustry, Forma Therapeutics Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forma Therapeutics Holdings's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forma Therapeutics Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Forma Therapeutics Holdings's Debt-to-EBITDA falls into.

Forma Therapeutics Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Forma Therapeutics Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(5.125	+	27.617)	/	-172.417
	=	-0.19

Forma Therapeutics Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(5.335	+	27.213)	/	-209.132
	=	-0.16

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.

Forma Therapeutics Holdings (NAS:FMTX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Forma Therapeutics Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Forma Therapeutics Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forma Therapeutics Holdings Inc (NAS:FMTX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 North Beacon Street, Suite 501, Watertown, MA, USA, 02472

Website

https://www.formatherapeutics.com

Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.

Executives

Agustin Melian	officer: EVP, Research & Development	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Brian Andrew Lesser	officer: SVP, Commercial Officer	C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET SUITE 501 WATERTOWN MA 02472
Mary E. Wadlinger	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Jeannette Potts	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Frank D. Lee	director, officer: President and CEO	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
David N Cook	officer: SVP, Chief Scientific Officer
Patrick F. Kelly	officer: SVP, Chief Medical Officer	C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Todd Shegog	officer: SVP, Chief Financial Officer	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Arturo Md Molina	director	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
John E Bishop	officer: Chief Technology Officer	675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Vickers Selwyn M Md	director	600 NORTH 18TH STREET, BIRMINGHAM AL 35203
Thomas G Wiggans	director
Frederick Wayne A.i.	director	500 W MAIN ST., LOUISVILLE KY 40202
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116